Posted by Michael Wonder on 22 Jan 2026
PHARMAC proposes to fund life changing treatments for people with cystic fibrosis
22 January 2026 - PHARMAC is proposing to fund new treatment options for people living with cystic fibrosis with eligible mutations, including young children, from 1 April 2026.
The proposal includes wider access to Trikafta (elexacaftor/tezacaftor/ivacaftor) and Kalydeco (ivacaftor) for all people with eligible mutations, and funding a new medicine, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).
